생물제제 시장 규모, 점유율, 성장 분석 : 유형별, 약제 클래스별, 치료 용도별, 공급원별, 제조업별, 지역별 - 산업 예측(2025년)
Biologics Market Size, Share, and Growth Analysis, By Type (Tumor Necrosis Factor Inhibitor, T-cell Inhibitor), By Drug Class, By Therapeutic Application, By Source, By Manufacturing, By Region - Industry Forecast 2025-2032
상품코드:1681598
리서치사:SkyQuest
발행일:2025년 03월
페이지 정보:영문 219 Pages
라이선스 & 가격 (부가세 별도)
한글목차
생물제제 시장 규모는 2023년에 5,113억 달러로 평가되며, 2024년 5,675억 4,000만 달러에서 2032년에는 1조 3,079억 2,000만 달러로 성장하며, 예측 기간(2025-2032년)의 CAGR은 11.0%로 성장할 전망입니다.
세계 바이오의약품 시장은 생명공학 기술의 발전과 표적치료제에 대한 수요 증가에 힘입어 견고한 성장세를 보이고 있습니다. 생물 유래 의약 화합물인 생물제제는 암, 자가면역질환, 감염성 질환 등 만성질환 치료의 전망을 크게 바꾸어 놓았습니다. 맞춤형의 혁신적인 접근 방식은 환자의 예후를 개선하고 바이오의약품을 현대 의료의 중요한 요소로 자리매김하고 있습니다. 시장 성장의 주요 촉진요인으로는 당뇨병, 관절염과 같은 만성질환의 확산과 효과적인 치료 옵션의 필요성이 대두되고 있다는 점을 꼽을 수 있습니다. 그러나 온도와 환경 조건의 영향을 받아 공급망 전체에 걸쳐 이러한 생물제제의 무결성을 유지하는 것은 여전히 과제로 남아있습니다. 미국 바이오의약품 시장은 지속적인 성장이 예상되며, 삶의 질 향상과 질병 관리에 있으며, 바이오의약품의 유망한 잠재력을 보여주고 있습니다.
목차
서론
조사의 목적
조사 범위
정의
조사 방법
정보 조달
2차와 1차 데이터 방법
시장 규모 예측
시장의 전제조건과 제한
개요
세계 시장 전망
공급과 수요 동향 분석
부문별 기회 분석
시장 역학과 전망
시장 개요
시장 규모
시장 역학
촉진요인과 기회
억제요인과 과제
Porter의 산업 분석
주요 시장 인사이트
주요 성공 요인
경쟁의 정도
주요 투자 기회
시장 에코시스템
시장의 매력 지수(2024년)
PESTEL 분석
거시경제 지표
밸류체인 분석
가격 분석
생물제제 시장 규모 : 유형별
시장 개요
종양괴사인자(TNF) 저해제
T세포 저해제
선택적 공자극 조절제
인터류킨-6(IL-6) 또는 인터류킨-17 블로커
인터류킨-1(IL-1) 블로커
B세포 저해제
생물제제 시장 규모 : 약제 클래스별
시장 개요
모노클로널 항체
재조합 인슐린
백신
혈액 인자
인간성장호르몬
에리스로포이에틴
융합단백질
재조합 효소
인터페론
콜로니자극인자
유전자 치료
세포치료
올리고뉴클레오티드
기타
펩티드
보툴리눔톡신(보톡스)
기타
생물제제 시장 규모 : 치료 용도별
시장 개요
종양학
자가면역질환/면역 질환
대사장애
안과 질환
호흡기질환
염증성장질환(IBD)
신경질환
심혈관질환(CVD)
근골격 장애(MSD)
감염증
기타
생물제제 시장 규모 : 공급원별
시장 개요
미생물
포유류
기타
생물제제 시장 규모 : 제조업별
시장 개요
아웃소싱
사내 제조
생물제제 시장 규모 : 약 유형별
시장 개요
브랜드 의약품
제네릭 의약품
생물제제 시장 규모 : 구입 방법별
시장 개요
처방약
일반의약품(OTC)
생물제제 시장 규모 : 제형별
시장 개요
주사
정제
기타
생물제제 시장 규모 : 투여 경로별
시장 개요
비경구
경구
기타
생물제제 시장 규모 : 최종사용자별
시장 개요
병원
전문 클리닉
홈케어
기타
생물제제 시장 규모 : 유통 채널별
시장 개요
병원 약국
소매 약국
온라인 약국
기타
생물제제 시장 규모
북미
미국
캐나다
유럽
독일
스페인
프랑스
영국
이탈리아
기타 유럽 지역
아시아태평양
중국
인도
일본
한국
기타 아시아태평양
라틴아메리카
브라질
기타 라틴아메리카 지역
중동 및 아프리카
GCC 국가
남아프리카공화국
기타 중동 및 아프리카
경쟁 정보
상위 5사의 비교
주요 기업의 시장 포지셔닝(2024년)
주요 시장 기업이 채택한 전략
최근 시장 동향
기업의 시장 점유율 분석(2024년)
주요 기업의 기업 개요
기업의 상세
제품 포트폴리오 분석
기업의 부문별 점유율 분석
매출의 전년대비 비교(2022-2024년)
주요 기업 개요
Roche Holding AG(Switzerland)
Johnson & Johnson(USA)
AbbVie Inc.(USA)
Novartis AG(Switzerland)
Amgen Inc.(USA)
Merck & Co., Inc.(USA)
Bristol Myers Squibb(USA)
Eli Lilly and Company(USA)
AstraZeneca plc(UK)
Biogen Inc.(USA)
Gilead Sciences, Inc.(USA)
Regeneron Pharmaceuticals, Inc.(USA)
Takeda Pharmaceutical Company Limited(Japan)
Boehringer Ingelheim(Germany)
Samsung Biologics(South Korea)
Lonza Group AG(Switzerland)
WuXi Biologics(China)
Celltrion, Inc.(South Korea)
Grifols, S.A.(Spain)
결론과 제안
KSA
영문 목차
영문목차
Biologics Market size was valued at USD 511.3 billion in 2023 and is poised to grow from USD 567.54 billion in 2024 to USD 1307.92 billion by 2032, growing at a CAGR of 11.0% during the forecast period (2025-2032).
The global biologics market has demonstrated robust growth, driven by advancements in biotechnology and the rising demand for targeted therapies. Biologics, pharmaceutical compounds sourced from living organisms, have shifted the landscape of treatment for chronic conditions, including cancer, autoimmune disorders, and infectious diseases. Their tailored and innovative approaches enhance patient outcomes, positioning biopharmaceuticals as critical components in modern healthcare. Key market growth drivers include the escalating prevalence of chronic diseases, such as diabetes and arthritis, necessitating effective treatment options. However, challenges remain in maintaining the integrity of these biologics throughout the supply chain, influenced by temperature and environmental conditions. The US biologics market is set for sustained growth, indicating promising prospects for biopharmaceuticals in improving quality of life and disease management.
Top-down and bottom-up approaches were used to estimate and validate the size of the Biologics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Biologics Market Segments Analysis
Global Biologics Market is segmented by Type, Drug Class, Therapeutic Application, Source, Manufacturing, Drug Type, Mode of Purchase, Dosage Form, Route of Administration, End-Users, Distribution Channel and region. Based on Type, the market is segmented into Tumor Necrosis Factor (TNF) Inhibitor, T-cell Inhibitor, Selective Co-stimulation Modulators, Interleukin-6 (IL-6) or Interleukin-17 Blocker, Interleukin-1 (IL-1) Blocker and B-cell Inhibitor. Based on Drug Class, the market is segmented into Monoclonal Antibody, Recombinant Insulin, Vaccine, Blood Factor, Human Growth Hormone, Erythropoietin, Fusion Protein, Recombinant Enzyme, Interferon, Colony-stimulating Factor, Gene Therapy, Peptide, Botulinum Toxin and Others. Based on Therapeutic Application, the market is segmented into Oncology, Autoimmune/Immunologic Diseases, Metabolic Disorders, Ophthalmic Diseases, Respiratory Disorders, Inflammatory Bowel Diseases (IBDs), Neurological Disorders, Cardiovascular Diseases (CVDs), Musculoskeletal Disorders (MSDs), Infectious Diseases and Others. Based on Source, the market is segmented into Microbial, Mammalian and Others. Based on Manufacturing, the market is segmented into Outsourced and In-House. Based on Drug Type, the market is segmented into Branded Drugs and Generic Drugs. Based on Mode of Purchase, the market is segmented into Prescription Drugs and Over-The-Counter (OTC) Drugs. Based on Dosage Form, the market is segmented into Injection, Tablets and Others. Based on Route of Administration, the market is segmented into Parenteral, Oral and Others. Based on End-Users, the market is segmented into Hospitals, Specialty Clinics, Homecare and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Biologics Market
The rising prevalence of chronic diseases, including cancer, diabetes, and autoimmune disorders, has significantly spurred the demand for innovative biological therapies. These advanced treatments leverage targeted approaches, distinguishing them from traditional chemical-based medications and enhancing their effectiveness. As a result, the biologics market is experiencing substantial growth, driven by the need for more precise and efficient therapeutic options. This trend reflects a broader shift toward personalized medicine, where tailored treatments not only improve patient outcomes but also foster ongoing advancements in biopharmaceutical research and development, further propelling the market forward.
Restraints in the Biologics Market
The biologics market faces significant challenges due to the intricate and expensive processes involved in the development and production of natural products. The stringent regulatory standards in place can limit both the affordability and accessibility of biologic therapies, ultimately hindering market growth. As companies navigate these challenges, the high costs associated with compliance and manufacturing may deter investment and innovation, which could further stifle advancements in biologic treatments. Consequently, the interplay between regulatory demands and production complexities remains a critical restraint for the biologics market, impacting its overall potential and reach in the healthcare industry.
Market Trends of the Biologics Market
The Biologics market is witnessing a significant shift towards personalized medicine, fundamentally transforming therapeutic approaches. This trend emphasizes the development of biologic therapies tailored to the unique genetic profiles and specific disease characteristics of individual patients, leading to more effective and targeted treatments. As a result, innovation in biological sciences is accelerating, with advancements in areas such as monoclonal antibodies, gene therapies, and regenerative medicine. The growing demand for precision therapies is propelling investments and research in this field, expanding the scope and applications of biologics in managing various diseases, thus positioning the market for robust growth in the coming years.
Table of Contents
Introduction
Objectives of the Study
Scope of the Report
Definitions
Research Methodology
Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations
Executive Summary
Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis
Market Dynamics & Outlook
Market Overview
Market Size
Market Dynamics
Drivers & Opportunities
Restraints & Challenges
Porters Analysis
Competitive rivalry
Threat of substitute
Bargaining power of buyers
Threat of new entrants
Bargaining power of suppliers
Key Market Insights
Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Global Biologics Market Size by Type & CAGR (2025-2032)
Market Overview
Tumor Necrosis Factor (TNF) Inhibitor
T-cell Inhibitor
Selective Co-stimulation Modulators
Interleukin-6 (IL-6) or Interleukin-17 Blocker
Interleukin-1 (IL-1) Blocker
B-cell Inhibitor
Global Biologics Market Size by Drug Class & CAGR (2025-2032)
Market Overview
Monoclonal Antibody
Recombinant Insulin
Vaccine
Blood Factor
Human Growth Hormone
Erythropoietin
Fusion Protein
Recombinant Enzyme
Interferon
Colony-stimulating Factor
Gene Therapy
Cell Therapy
Oligonucleotides
Others
Peptide
Botulinum Toxin
Others
Global Biologics Market Size by Therapeutic Application & CAGR (2025-2032)
Market Overview
Oncology
Autoimmune/Immunologic Diseases
Metabolic Disorders
Ophthalmic Diseases
Respiratory Disorders
Inflammatory Bowel Diseases (IBDs)
Neurological Disorders
Cardiovascular Diseases (CVDs)
Musculoskeletal Disorders (MSDs)
Infectious Diseases
Others
Global Biologics Market Size by Source & CAGR (2025-2032)
Market Overview
Microbial
Mammalian
Others
Global Biologics Market Size by Manufacturing & CAGR (2025-2032)
Market Overview
Outsourced
In-House
Global Biologics Market Size by Drug Type & CAGR (2025-2032)
Market Overview
Branded Drugs
Generic Drugs
Global Biologics Market Size by Mode of Purchase & CAGR (2025-2032)
Market Overview
Prescription Drugs
Over-The-Counter (OTC) Drugs
Global Biologics Market Size by Dosage Form & CAGR (2025-2032)
Market Overview
Injection
Tablets
Others
Global Biologics Market Size by Route of Administration & CAGR (2025-2032)
Market Overview
Parenteral
Oral
Others
Global Biologics Market Size by End-Users & CAGR (2025-2032)
Market Overview
Hospitals
Specialty Clinics
Homecare
Others
Global Biologics Market Size by Distribution Channel & CAGR (2025-2032)
Market Overview
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Others
Global Biologics Market Size & CAGR (2025-2032)
North America (Type, Drug Class, Therapeutic Application, Source, Manufacturing, Drug Type, Mode of Purchase, Dosage Form, Route of Administration, End-Users, Distribution Channel)
US
Canada
Europe (Type, Drug Class, Therapeutic Application, Source, Manufacturing, Drug Type, Mode of Purchase, Dosage Form, Route of Administration, End-Users, Distribution Channel)
Germany
Spain
France
UK
Italy
Rest of Europe
Asia Pacific (Type, Drug Class, Therapeutic Application, Source, Manufacturing, Drug Type, Mode of Purchase, Dosage Form, Route of Administration, End-Users, Distribution Channel)
China
India
Japan
South Korea
Rest of Asia-Pacific
Latin America (Type, Drug Class, Therapeutic Application, Source, Manufacturing, Drug Type, Mode of Purchase, Dosage Form, Route of Administration, End-Users, Distribution Channel)
Brazil
Rest of Latin America
Middle East & Africa (Type, Drug Class, Therapeutic Application, Source, Manufacturing, Drug Type, Mode of Purchase, Dosage Form, Route of Administration, End-Users, Distribution Channel)
